Acetyl-TP53 (K317) Antibody

What is the Acetyl-TP53 (K317) Antibody and what specific modification does it detect?

The Acetyl-TP53 (K317) Antibody is a polyclonal antibody that specifically recognizes p53 protein only when acetylated at lysine 317 (K317 in mouse, corresponding to K320 in humans). This antibody has been generated using synthesized peptides derived from human p53 around the acetylation site of K317, typically within the amino acid range 283-332 . The antibody specifically detects endogenous levels of p53 protein that have undergone this post-translational modification, allowing researchers to study the acetylation status of p53 at this specific lysine residue .

What are the primary applications for Acetyl-TP53 (K317) Antibody in research?

The Acetyl-TP53 (K317) Antibody has been validated for multiple research applications:

These applications enable researchers to examine both the expression levels and cellular localization of acetylated p53 at K317 in various experimental models .

What is the biological significance of p53 acetylation at K317/K320?

P53 acetylation at K317 (mouse)/K320 (human) plays a crucial role in regulating the balance between cell cycle arrest and apoptosis:

• Studies using p53K317R knock-in mice (where lysine 317 was replaced with arginine to prevent acetylation) demonstrated that acetylation at this residue negatively regulates p53-mediated apoptosis following DNA damage .

• When K317 is acetylated, p53 preferentially activates genes involved in cell cycle arrest while suppressing the expression of pro-apoptotic genes .

• PCAF (p300-CBP associated factor) has been identified as the acetyltransferase responsible for acetylating p53 at K320 in humans .

• This site-specific acetylation creates a molecular switch that influences p53's decision between promoting cell survival (through DNA repair and cell cycle arrest) versus triggering cell death .

What are the optimal sample preparation methods when using Acetyl-TP53 (K317) Antibody?

For optimal detection of acetylated p53 at K317, consider the following sample preparation approaches:

• Cell treatment conditions:

  • Treatment with DNA-damaging agents (e.g., adriamycin, UV irradiation) induces p53 acetylation .

  • Co-treatment with histone deacetylase (HDAC) inhibitors such as trichostatin A (TSA, 5 μM for 2-4 hours) significantly enhances detection of acetylated forms .

  • For optimal detection, prepare samples 8-18 hours after DNA damage induction .

• Protein extraction:

  • Whole-cell extracts are suitable for most applications.

  • For enhanced detection, immunoprecipitation of p53 followed by western blotting with the acetylation-specific antibody can be performed .

  • Use freshly prepared protease inhibitors and deacetylase inhibitors in lysis buffers to prevent loss of acetylation during extraction.

• Controls:

  • Positive controls: HeLa cells, NIH/3T3 cells, or C6 cells treated with TSA .

  • Negative controls: Untreated cells or cells expressing acetylation-deficient mutants (K317R) .

How can I validate the specificity of the Acetyl-TP53 (K317) Antibody?

To ensure antibody specificity, implement these validation strategies:

• Comparative analysis with acetylation-deficient mutants:

  • Use cells expressing p53-K317R mutants as negative controls .

  • Compare reactivity between wild-type and mutant samples following DNA damage.

• Peptide competition assays:

  • Pre-incubate the antibody with increasing concentrations of the acetylated peptide used as immunogen.

  • A specific antibody will show decreased signal when pre-incubated with the cognate peptide.

• HDAC inhibitor treatment:

  • Compare samples with and without HDAC inhibitor treatment (e.g., TSA).

  • Increased signal following HDAC inhibition confirms detection of acetylated p53 .

• Immunodepletion:

  • Sequential immunoprecipitation with total p53 antibody followed by probing the depleted lysate with the acetylation-specific antibody.

How does acetylation at K317/K320 interact with other post-translational modifications of p53?

P53 undergoes multiple post-translational modifications that form a complex regulatory network:

• Interplay with other acetylation sites:

  • Unlike C-terminal acetylation sites (K370, K372, K373, K381, K382), which primarily enhance p53 stability and DNA binding, K317/K320 acetylation specifically affects target gene selectivity .

  • Studies have shown that different acetylation patterns can lead to distinct p53 transcriptional programs; K317/K320 acetylation favors cell cycle arrest genes over apoptotic genes .

• Crosstalk with phosphorylation:

  • Phosphorylation events, particularly at serine residues following DNA damage, can precede and influence acetylation patterns .

  • Experiments in p53K317R mice revealed that while phosphorylation at Ser18 occurred normally, the expression pattern of p53 target genes was altered, demonstrating that these modifications work in concert but have distinct roles .

• Relationship with methylation and ubiquitination:

  • The acetylation status of p53 affects its interaction with ubiquitin ligases like MDM2 .

  • Adjacent modifications can influence K317 acetylation detection; for example, phosphorylation of nearby residues (T377, S378) does not enhance K382me2 antibody recognition, suggesting site-specific interactions .

What are the methodological considerations when examining p53 K317 acetylation in different experimental models?

When studying p53 K317 acetylation across different models, researchers should consider:

• Species-specific differences:

  • Mouse K317 corresponds to human K320; ensure your antibody recognizes the appropriate species-specific epitope .

  • Sequence analysis reveals this acetylation site is conserved across species including human, mouse, Xenopus, and zebrafish, as well as in p53-related proteins p63 and p73 .

• Cell type-specific responses:

  • The role of p53 acetylation varies by cell type; for example, p53K317R mice showed increased apoptosis in thymocytes, intestinal epithelial cells, and retinal cells after irradiation .

  • In colorectal cancer cells (HCT116), loss of p300-mediated p53 acetylation increased pro-apoptotic gene expression, suggesting context-dependent effects .

• Stress-specific acetylation patterns:

  • Different stressors induce distinct acetylation patterns; DNA damage via adriamycin versus UV irradiation may result in different levels of K317 acetylation .

  • Time-course experiments are essential as acetylation is a dynamic process with temporal variations after stress induction .

How can Acetyl-TP53 (K317) Antibody be used to investigate the mechanism of action of deacetylases?

The antibody can be employed to study deacetylase function through several approaches:

• SIRT1 regulation of p53:

  • SIRT1-deficient mouse embryonic fibroblasts (MEFs) exhibit hyperacetylation of p53 at multiple sites including K317, suggesting SIRT1 regulates p53 acetylation .

  • Researchers can use the antibody to assess how SIRT1 modulators affect K317 acetylation status as SIRT1 has been shown to regulate p53 activity .

• Pharmacological studies:

  • Treatment with deacetylase inhibitors like TSA can be monitored using the antibody to assess site-specific effects on K317 .

  • Dose-response and time-course experiments can reveal the kinetics of acetylation/deacetylation at this specific site.

• Genetic manipulation approaches:

  • Complementation studies using SIRT1-deficient cells reconstituted with wild-type or mutant SIRT1 showed restoration of normal p53 acetylation levels, demonstrating a causal relationship .

  • Similar approaches can be used to investigate other deacetylases that may regulate K317 acetylation.

What are common challenges in detecting acetylated p53 at K317 and how can they be addressed?

Researchers frequently encounter these challenges when working with acetylation-specific antibodies:

• Low signal intensity:

  • Enhance acetylation levels by co-treating cells with deacetylase inhibitors (TSA 5 μM for 2-4 hours) .

  • Optimize antibody concentration; recommended dilutions range from 1:500-1:2000 for WB but may require adjustment .

  • Consider immunoprecipitating p53 first to concentrate the target protein before detection .

• High background:

  • Increase blocking time and concentration (5% non-fat dry milk in TBS-T is recommended) .

  • Ensure proper antibody dilution and washing steps.

  • Use acetylation-deficient mutants (K317R) as negative controls to distinguish specific from non-specific signals .

• Inconsistent results between experiments:

  • Standardize cell treatment conditions, as acetylation status is highly dynamic.

  • Control for p53 stabilization, as total p53 levels affect detection of modified forms.

  • Use fresh reagents and avoid repeated freeze-thaw cycles of antibody (store at -20°C or -80°C) .

How should researchers interpret complex acetylation patterns when using multiple p53 acetylation-specific antibodies?

When analyzing multiple acetylation sites simultaneously:

• Differential acetylation kinetics:

  • Different lysine residues show distinct acetylation/deacetylation kinetics and may require site-specific optimization.

  • Studies have shown that following DNA damage, p53 acetylation occurs at multiple sites including K317, K370, K372, K373, K381, K382, and K164, but with different temporal patterns .

• Combinatorial modifications:

  • Adjacent modifications can influence antibody recognition; for example, acetylation at K381 enhances recognition of K382me2 by specific antibodies .

  • Consider creating a modification pattern map to interpret the combined significance of multiple modifications.

• Comparative analysis approaches:

  • Use acetylation-defective mutants (e.g., K317R, 6KR, 7KR, 8KR) to establish site-specific contributions .

  • Acetylation-mimicking mutants (K to Q) can help interpret the functional significance of observed patterns .

How can researchers resolve contradictory results when studying p53 K317 acetylation in different experimental systems?

When faced with contradictory findings:

• Cell type and context considerations:

  • The effect of K317 acetylation varies by cell type; p53K317R mutations showed increased apoptosis in thymocytes but different effects in other cell types .

  • Document all experimental variables, including cell type, passage number, confluence, and treatment conditions.

• Technical factors:

  • Antibody specificity may vary between manufacturers; validate using appropriate controls in your specific system.

  • Differences in sample preparation can affect detection; standardize protocols for consistent results.

• Biological complexity:

  • p53 function is regulated by complex networks of modifications; a single modification like K317 acetylation may have different outcomes depending on the status of other modifications.

  • Consider using systems biology approaches to model the combinatorial effects of multiple modifications.

How can Acetyl-TP53 (K317) Antibody be utilized in investigating the p53 conformational changes induced by post-translational modifications?

Recent research reveals that acetylation can drive conformational changes in p53:

• Structural studies:

  • Crystal structure analysis at 1.8 Å resolution demonstrated that dual post-translational modifications (acetylation at K381 and dimethylation at K382) induced a conformational change in p53 that affected its interaction with binding partners .

  • Similar approaches could investigate whether K317 acetylation induces conformational changes that affect target gene selectivity.

• Protein-protein interaction studies:

  • Acetylation at specific sites modulates p53 interactions with cofactors; K317 acetylation may specifically influence interactions with cell cycle regulatory proteins .

  • Techniques such as co-immunoprecipitation or proximity ligation assays using the Acetyl-TP53 (K317) Antibody could reveal modification-specific interactors.

• Novel technologies:

  • Combining site-specific acetylation antibodies with FRET-based approaches could visualize conformation changes in living cells.

  • Mass spectrometry approaches can provide comprehensive mapping of modifications that co-occur with K317 acetylation.

What is the potential for developing therapeutic strategies targeting p53 K317 acetylation in cancer treatment?

The critical role of K317/K320 acetylation in regulating p53 function suggests therapeutic opportunities:

• Targeted modulation of K317 acetylation:

  • Since K317 acetylation negatively regulates apoptosis in response to DNA damage, inhibiting this specific acetylation could potentially enhance the efficacy of DNA-damaging chemotherapeutics .

  • Development of site-specific modulators that affect PCAF activity toward p53 could provide precision tools for cancer therapy.

• Diagnostic applications:

  • The acetylation status of p53 at K317 could serve as a biomarker for predicting tumor response to specific therapies.

  • The Acetyl-TP53 (K317) Antibody could be utilized in developing diagnostic assays to assess this modification in tumor samples.

• Combination therapy approaches:

  • Understanding how K317 acetylation interfaces with other p53 modifications could inform rational combination therapy strategies.

  • For instance, combining HDAC inhibitors with agents that target specific acetylation readers could provide synergistic effects.

How might single-cell analysis techniques benefit from Acetyl-TP53 (K317) Antibody to understand heterogeneity in p53 responses?

Emerging single-cell technologies offer new opportunities:

• Single-cell western blotting:

  • Adaptation of the Acetyl-TP53 (K317) Antibody for microfluidic single-cell western blotting could reveal cell-to-cell variation in p53 acetylation status within populations.

• Mass cytometry (CyTOF):

  • Metal-conjugated Acetyl-TP53 (K317) Antibody could be used in mass cytometry to simultaneously measure multiple p53 modifications at the single-cell level.

  • This approach could reveal how acetylation patterns correlate with cell fate decisions in heterogeneous populations.

• Spatial transcriptomics integration:

  • Combining immunofluorescence using the Acetyl-TP53 (K317) Antibody with spatial transcriptomics could map relationships between p53 acetylation status and downstream gene expression patterns in tissues.